CD8A and COVID-19: Patients with COVID-19-induced ARDS had a significantly increased proportion of activated-state T cells, including the CD8+ T_Effector_GZMA subpopulation (Figure 4F), which were present at high rates in patients with COVID-19-induced ARDS.